Catalyst

Slingshot members are tracking this event:

Phase III trial with PM1183 in ovarian cancer (CORAIL) continues on the basis of positive recommendation by IDMC

Source Link:
http://www.pharmamar.com/wp-content/uploads/2016/02/PR_Positive-recommendation-IDMC.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PHM.MC Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The IDMC's recommendation came after an analysis of the safety data obtained with the first 80 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 compared with the standard treatment for this indication—topotecan or pegylated liposomal doxorubicin—in a total of 420 patients. 
http://www.pharmamar...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 08, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase Iii Trial, Pm1183, Ovarian Cancer, Corail, Idmc, Platinum-resistant Ovarian Cancer, Topotecan, Pegylated Liposomal Doxorubicin
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.